Immunotech Laboratories (OTCPK:IMMB) - Stock Price, News & Analysis

IMMB Stock Overview

Develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. More details

IMMB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($57K)

Shares are highly illiquid

Immunotech Laboratories, Inc. Competitors

Histogen

OTCPK:HSTO.Q

US$85.4k

Innovation Pharmaceuticals

OTCPK:IPIX

US$264.4k

Allena Pharmaceuticals

OTCPK:ALNA.Q

US$109.9k

Vaxxinity

OTCPK:VAXX

US$12.7k

Price History & Performance

Summary of all time highs, changes and price drops for Immunotech Laboratories
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.0001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
33 Year Change	-90.00%
5 Year Change	0%
Change since IPO	-99.97%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IMMB	US Biotechs	US Market
7D	0%	2.4%	0.5%
1Y	0%	15.6%	30.7%

Return vs Industry: IMMB underperformed the US Biotechs industry which returned 15.6% over the past year.

Return vs Market: IMMB underperformed the US Market which returned 30.7% over the past year.

Price Volatility

Is IMMB's price volatile compared to industry and market?
IMMB volatility
IMMB Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IMMB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IMMB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	www.immunotechlab.com

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California.

Immunotech Laboratories, Inc. Fundamentals Summary

How do Immunotech Laboratories's earnings and revenue compare to its market cap?
IMMB fundamental statistics
Market cap	US$57.50k
Earnings (TTM)	-US$977.57k
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IMMB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$977.57k
Earnings	-US$977.57k

Last Reported Earnings

Dec 31, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IMMB perform over the long term?

See historical performance and comparison